Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

The role of palliative care in the multidisciplinary treatment of immunoglobulin light chain amyloidosis

Pedro Vianna, Joshua Lakin, Samantha Gelfand, Eilann Santo, Brigitte Durieux, Shannon Miller, Shahrier Hossain, Jacob Laubach, Giada Bianchi

Blood (2025) 146 (Supplement 1): 8152.

https://doi.org/10.1182/blood-2025-8152

Published: 2025

Journal Articles

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

Blood (2025) 146 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2025-2182

Published: 2025

Journal Articles

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

Blood (2025) 146 (Supplement 1): 261.

https://doi.org/10.1182/blood-2025-261

Published: 2025

Journal Articles

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Shahrier Hossain, Adam Sperling, Jacob Laubach, Shannon Miller, Pedro Vianna, Emily Simpson, Madison Chuma, Brendan Fink, Samantha Geberth, Emily Magnavita, Jack Khouri, James Hoffman, Jonathan Kaufman, Vaishali Sanchorawala, Raymond Comenzo, Giada Bianchi

Blood (2025) 146 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2025-5808

Published: 2025

Journal Articles

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, Divaya Bhutani, Shannon Miller, Annemarie Rossi, Sarah A. M. Cuddy, Rodney H. Falk, Suzanne Lentzsch, Jacob P. Laubach, Giada Bianchi

Blood (2025) 146 (16): 1929–1935.

https://doi.org/10.1182/blood.2025028383

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Blood (2025) 146 (12): 1476–1492.

https://doi.org/10.1182/blood.2024024719

Published: 2025

Includes: Supplemental data

Journal Articles

Moving forward in good KarMMa in myeloma

Giada Bianchi

Blood (2024) 144 (23): 2367–2369.

https://doi.org/10.1182/blood.2024026428

Published: 2024

Journal Articles

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Brendan Saunders, Foteini Theodorakakou, Benjamin Evans, Samuel Boullt, Despina Fotiou, Meletios Dimopoulos, Efstathios Kastritis, Giada Bianchi

Blood (2024) 144 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2024-204612

Published: 2024

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis

Pedro G Vianna, Shahrier Hossain, Shannon Miller, Annemarie Rossi, Sarah AM Cuddy, Rodney H Falk, Jacob P. Laubach, Giada Bianchi

Blood (2024) 144 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2024-200933

Published: 2024

Journal Articles

Systematic Annotation of Secretory Pathway Genes As a Discovery Tool for New Therapeutic Targets in AL Amyloidosis

Brendan Saunders, Carlos Quetglas, Dirk Fasshauer, Suzanne Elsasser, Giada Bianchi

Blood (2024) 144 (Supplement 1): 6835.

https://doi.org/10.1182/blood-2024-210683

Published: 2024

Journal Articles

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Nadine Abdallah, Jay R. Hydren, Mason S. Barnes, Andrew Wood, Sascha Alexander Tuchman, Jeffrey A. Zonder, Giada Bianchi, Heather J. Landau, Muhamed Baljevic, James E. Hoffman, Ana M. Sahagun Sanchez Aldana, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 5143.

https://doi.org/10.1182/blood-2024-208737

Published: 2024

Journal Articles

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1928.

https://doi.org/10.1182/blood-2024-203684

Published: 2024

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis

Emre Karayol, Maria Moscvin, Tianzeng Chen, Peter G. Czarnecki, Annamaria Gulla, Kenneth C. Anderson, Giada Bianchi

Blood (2023) 142 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2023-177714

Published: 2023

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Paolo Lopedote, Alfredo Marchetti, Benjamin Evans, Tianzeng Chen, Maria Moscvin, Niccolò Bolli, Giada Bianchi

Blood (2023) 142 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2023-190905

Published: 2023

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10180–10181.

https://doi.org/10.1182/blood-2022-165512

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The role of palliative care in the multidisciplinary treatment of immunoglobulin light chain amyloidosis

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Moving forward in good KarMMa in myeloma

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis

Systematic Annotation of Secretory Pathway Genes As a Discovery Tool for New Therapeutic Targets in AL Amyloidosis

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only